Baseline patient characteristics by BMI
| Abatacept (n=212) | Placebo (n=210) | |||||
| Underweight/normal (n=31) | Overweight (n=77) | Obese (n=104) | Underweight/normal (n=39) | Overweight (n=57) | Obese (n=114) | |
| Age, years | 52.4 (11.3) | 49.8 (10.5) | 51.5 (10.7) | 46.1 (11.8) | 48.6 (10.7) | 51.8 (11.0) |
| Female (%) | 67.7 | 42.9 | 63.5 | 41.0 | 40.4 | 64.0 |
| BMI | 22.6 (1.7) | 27.5 (1.5) | 35.4 (5.5) | 22.9 (1.6) | 27.5 (1.4) | 36.0 (5.4) |
| Weight, kg | 61.9 (9.4) | 77.6 (10.4) | 97.2 (18.8) | 64.0 (9.7) | 79.1 (9.6) | 98.0 (19.3) |
| Prior TNFi, n (%) | 20 (64.5) | 51 (66.2) | 57 (54.8) | 22 (53.9) | 31 (54.4) | 75 (65.8) |
| Concomitant MTX, n (%) | 23 (74.2) | 43 (55.8) | 62 (59.6) | 28 (71.8) | 36 (63.2) | 61 (53.5) |
| Concomitant oral corticosteroids, n (%) | 10 (32.3) | 21 (27.3) | 22 (21.2) | 11 (28.2) | 11 (19.3) | 26 (22.8) |
| PsA duration, years | 9.0 (8.0) | 7.6 (7.5) | 8.6 (8.7) | 9.1 (8.8) | 9.4 (8.7) | 8.4 (8.0) |
| TJC(68) | 18.6 (14.6) | 20.1 (14.1) | 22.3 (12.4) | 15.8 (11.2) | 17.9 (11.9) | 20.9 (13.7) |
| SJC(66) | 10.6 (8.6) | 10.9 (6.4) | 13.4 (8.4) | 10.1 (5.5) | 11.1 (7.2) | 11.5 (7.6) |
| HAQ-DI | n=30 1.3 (0.6) | 1.3 (0.7) | 1.3 (0.8) | 1.1 (0.8) | 1.2 (0.7) | 1.4 (0.7) |
| CRP, mg/L | 13.1 (23.7) | n=76 14.6 (25.7) | 13.9 (15.6) | 19.7 (54.6) | 11.1 (20.0) | n=112 14.1 (21.9) |
| DAS28 (CRP) | 4.8 (1.1) | n=75 5.0 (1.1) | n=103 5.1 (1.0) | 4.5 (1.2) | 4.8 (0.9) | n=111 5.1 (1.0) |
| Erosion score | n=29 9.1 (16.3) | n=75 13.5 (28.9) | n=101 14.0 (31.3) | 20.2 (27.8) | n=55 11.8 (29.4) | n=112 8.1 (20.0) |
| Dactylitis, n (%) | 13 (41.9) | 36 (46.8) | 43 (41.4) | 10 (25.6) | 26 (45.6) | 36 (31.6) |
| Enthesitis* | 2.1 (2.0) | 1.9 (1.8) | 2.2 (2.1) | 1.7 (2.0) | 2.1 (2.1) | 1.8 (1.9) |
| PASI† | n=23 5.6 (4.9) | n=54 6.3 (6.5) | n=69 8.7 (9.5) | n=30 5.0 (4.5) | n=43 7.0 (7.0) | n=75 8.2 (9.0) |
| PsA-modified total SHS | n=29 16.9 (32.7) | n=75 22.4 (50.0) | n=101 25.2 (56.2) | n=34 34.6 (47.8) | n=55 22.7 (54.9) | n=112 15.2 (39.7) |
| BASDAI | n=30 6.1 (2.0) | n=75 6.4 (2.1) | n=103 6.2 (2.1) | 5.9 (2.2) | n=56 6.1 (2.2) | n=113 6.3 (2.0) |
Data are expressed as mean (SD) unless otherwise noted.
Underweight/normal, BMI <25 kg/m2; overweight, BMI 25–30 kg/m2; obese, BMI >30 kg/m2.
*Measured using the Leeds Enthesitis Index.
†For patients with baseline BSA ≥3%.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass index; BSA, body surface area affected; CRP, C reactive protein; DAS28, Disease Activity Score in 28 joints; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SHS, Sharp/van der Heijde score; SJC, swollen joint count; TJC, tender joint count; TNFi, tumour necrosis factor inhibitor.